Association between serum levels of glial cell-line derived neurotrophic factor and attention deficits in schizophrenia

Neuroscience Letters

Volumn 575, Issue , 2014, Pages 37-41

  Niitsu, Tomihisa ^a   Shirayama, Yukihiko ^b   Matsuzawa, Daisuke ^a   Shimizu, Eiji ^a   Hashimoto, Kenji ^c   Iyo, Masaomi ^a,c  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Attention; Biomarker; Glial cell line derived neurotrophic factor (GDNF); Schizophrenia; Working memory

Indexed keywords

ARIPIPRAZOLE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; BIOLOGICAL MARKER;

AGE; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATIONAL STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SMOKING; WORKING MEMORY; ADULT; ATTENTION; BLOOD; CASE CONTROL STUDY; COGNITION; CROSS-SECTIONAL STUDY; PSYCHOLOGY;

ADULT; ATTENTION; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COGNITION; CROSS-SECTIONAL STUDIES; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MALE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84901953583     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.05.034     Document Type: Article

References (27)

1. Airaksinen M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 2002, 3:383-394.
2. Angelucci F., Brene S., Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 2005, 10:345-352.
3. Gerlai R., McNamara A., Choi-Lundberg D.L., Armanini M., Ross J., Powell-Braxton L., Phillips H.S. Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation. Eur. J. Neurosci. 2001, 14:1153-1163.
4. Ghitza U.E., Zhai H., Wu P., Airavaara M., Shaham Y., Lu L. Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci. Biobehav. Rev. 2010, 35:157-171.
5. Giakoumaki S.G. Cognitive and prepulse inhibition deficits in psychometrically high schizotypal subjects in the general population: relevance to schizophrenia research. J. Int. Neuropsychol. Soc. 2012, 18:643-656.
6. Golden J.P., DeMaro J.A., Osborne P.A., Milbrandt J., Johnson E.M. Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. Exp. Neurol. 1999, 158:504-528.
7. Gramage E., Herradon G. Connecting Parkinson's disease and drug addiction: common players reveal unexpected disease connections and novel therapeutic approaches. Curr. Pharm. Des. 2011, 17:449-461.
8. Harvey P.D., Koren D., Reichenberg A., Bowie C.R. Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr. Bull. 2006, 32:250-258.
9. Koike K., Hashimoto K., Takai N., Shimizu E., Komatsu N., Watanabe H., Nakazato M., Okamura N., Stevens K.E., Freedman R., Iyo M. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr. Res. 2005, 76:67-72.
10. Lee K., Kunugi H., Nanko S. Glial cell line-derived neurotrophic factor (GDNF) gene and schizophrenia: polymorphism screening and association analysis. Psychiatry Res. 2001, 104:11-17.
11. Ma X.C., Chen C., Zhu F., Jia W., Gao C.G. Association of the GDNF gene with depression and heroin dependence, but not schizophrenia, in a Chinese population. Psychiatry Res. 2013, 210:1296-1298.
12. Mickiewicz A.L., Kordower J.H. GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol. Disord.: Drug Targets 2011, 10:703-711.
13. Naumenko V.S., Bazovkina D.V., Morozova M.V., Popova N.K. Effects of brain-derived and glial cell line-derived neurotrophic factors on startle response and disrupted prepulse inhibition in mice of DBA/2J inbred strain. Neurosci. Lett. 2013, 550:115-118.
14. Niitsu T., Ishima T., Yoshida T., Hashimoto T., Matsuzawa D., Shirayama Y., Nakazato M., Shimizu E., Hashimoto K., Iyo M. A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res. 2013, 215:268-273.
15. Niitsu T., Shirayama Y., Matsuzawa D., Hasegawa T., Kanahara N., Hashimoto T., Shiraishi T., Shiina A., Fukami G., Fujisaki M., Watanabe H., Nakazato M., Asano M., Kimura S., Hashimoto K., Iyo M. Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2011, 35:1836-1840.
16. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72:29-39.
17. Okragly A.J., Haak-Frendscho M. An acid-treatment method for the enhanced detection of GDNF in biological samples. Exp. Neurol. 1997, 145:592-596.
18. Rosa A.R., Frey B.N., Andreazza A.C., Cereser K.M., Cunha A.B., Quevedo J., Santin A., Gottfried C., Goncalves C.A., Vieta E., Kapczinski F. Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci. Lett. 2006, 407:146-150.
19. Silver H., Feldman P., Bilker W., Gur R.C. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am. J. Psychiatry 2003, 160:1809-1816.
20. Sopova K., Gatsiou K., Stellos K., Laske C. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies. Curr. Alzheimer Res. 2014, 11:27-39.
21. Souza R.P., Romano-Silva M.A., Lieberman J.A., Meltzer H.Y., Macneil L.T., Culotti J.G., Kennedy J.L., Wong A.H. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. J. Psychiatr. Res. 2010, 44:700-706.
22. Straten G., Eschweiler G.W., Maetzler W., Laske C., Leyhe T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. J. Alzheimer's Dis. 2009, 18:331-337.
23. Takebayashi M., Hisaoka K., Nishida A., Tsuchioka M., Miyoshi I., Kozuru T., Hikasa S., Okamoto Y., Shinno H., Morinobu S., Yamawaki S. Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int. J. Neuropsychopharmacol. 2006, 9:607-612.
24. Uchida S., Hara K., Kobayashi A., Otsuki K., Yamagata H., Hobara T., Suzuki T., Miyata N., Watanabe Y. Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron 2011, 69:359-372.
25. Vingerhoets W.A., Bloemen O.J., Bakker G., van Amelsvoort T.A. Pharmacological interventions for the MATRICS cognitive domains in schizophrenia: what's the evidence?. Front. Psychiatry 2013, 4:157.
26. Zhang X., Zhang Z., Sha W., Xie C., Xi G., Zhou H., Zhang Y. Effect of treatment on serum glial cell line-derived neurotrophic factor in bipolar patients. J. Affective Disord. 2010, 126:326-329.
27. Zhang X., Zhang Z., Sha W., Xie C., Xi G., Zhou H., Zhang Y. Electroconvulsive therapy increases glial cell-line derived neurotrophic factor (GDNF) serum levels in patients with drug-resistant depression. Psychiatry Res. 2009, 170:273-275.